<SUBMISSION>
<ACCESSION-NUMBER>0000891836-00-000747
<TYPE>SC TO-T/A
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20001218
<GROUP-MEMBERS>KONINKLIJKE PHILIPS ELECTRONICS NV
<GROUP-MEMBERS>PHILIPS HOLDING USA INC.
<GROUP-MEMBERS>PHILIPS MEDICAL ACQUISITION CORPORATION
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>ADAC LABORATORIES
<CIK>0000313798
<ASSIGNED-SIC>3844
<IRS-NUMBER>941725806
<STATE-OF-INCORPORATION>CA
<FISCAL-YEAR-END>0930
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-T/A
<ACT>34
<FILE-NUMBER>005-32403
<FILM-NUMBER>791246
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>540 ALDER DR
<CITY>MILPITAS
<STATE>CA
<ZIP>95035
<PHONE>4083219100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>540 ALDER DR
<CITY>MILPITAS
<STATE>CA
<ZIP>95035
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>KONINKLIJKE PHILIPS ELECTRONICS NV
<CIK>0000313216
<ASSIGNED-SIC>3600
<STATE-OF-INCORPORATION>P7
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC TO-T/A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>REMBRANDT TOWER AMSTELPLEIN 1
<STREET2>1096 HA AMSTERDAM
<CITY>THE NETHERLANDS
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>REMBRANDT TOWER AMSTELPLEIN 1
<STREET2>1096 HA AMSTERDAM
<CITY>THE NETHERLANDS
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>PHILIPS ELECTRONICS N V
<DATE-CHANGED>19930727
</FORMER-COMPANY>
</FILED-BY>
<DOCUMENT>
<TYPE>SC TO-T/A
<SEQUENCE>1
<FILENAME>0001.htm
<DESCRIPTION>SCHEDULE TO, AMENDMENT NO. 9
<TEXT>

<HTML>
<HEAD>
<TITLE>
SCHEDULE TO, AMENDMENT NO. 9
</TITLE>
</HEAD>
<BODY>

<H5 Align=center>As filed with the Securities and Exchange Commission on December 18, 2000</H5>

<TABLE WIDTH=30%  ALIGN=RIGHT CELLPADDING=2 CELLSPACING=0 BORDER=2>
<TR>
     <TD ALIGN=CENTER>
     <B><FONT SIZE=-1>OMB APPROVAL</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>OMB Number: 3235-0515</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>Expires: January 31, 2002</FONT></B>
     </TD>
</TR>
<TR>
     <TD>
     <B><FONT SIZE=-1>Estimated average burden <BR>
     hours per response: 43.5</FONT></B>
     </TD>
</TR>
</TABLE>

<BR><BR><BR><BR><BR><BR><BR><BR>

<P ALIGN=CENTER>
<B><FONT SIZE=+1>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</FONT><BR>
Washington, D.C. 20549</B>
</P>

<P ALIGN=CENTER>
<FONT SIZE=+1><B>Schedule TO</B></FONT>
</P>

<P ALIGN=CENTER>
<B>Tender Offer Statement under Section 14(d)(1) or 13(e)(1)<BR>
of the Securities Exchange Act of 1934</B>
</P>

<P ALIGN=CENTER>
<B>(Amendment No. 9)</B>
</P>

<P ALIGN=CENTER>
<B>ADAC Laboratories<BR>
<BR>
<FONT SIZE=-2>(Name of Subject Company (Issuer))</FONT></B>
</P>

<P ALIGN=CENTER>
<B>Philips Medical Acquisition Corporation<BR>
<BR>
a Wholly Owned Subsidiary of<BR>
<BR>
Philips Holding USA Inc.<BR>
<BR>
a Wholly Owned Subsidiary of<BR>
<BR>
Koninklijke Philips Electronics N.V.<BR>
<BR>
<FONT SIZE=-2>(Names of Filing Persons)</FONT></B>

<P ALIGN=CENTER>
<B>COMMON STOCK,<BR>
NO PAR VALUE<BR>
<BR>
<FONT SIZE=-2>(Title of Class of Securities)</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>005313200<BR>
<BR>
(CUSIP Number of Class of Securities)</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>William E. Curran<BR>
<BR>
President<BR>
<BR>
Philips Holding USA Inc.<BR>
<BR>
1251 Avenue of the Americas<BR>
<BR>
New York, New York 10020</FONT></B>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-2>(Name, address, and telephone numbers of person authorized<BR>
to receive notices and communications on behalf of filing persons)</FONT></B>
</P>

<P ALIGN=CENTER>
<FONT SIZE=-1>with a copy to:</FONT>
</P>

<P ALIGN=CENTER>
<B><FONT SIZE=-1>Matthew G. Hurd<BR>
Sullivan &amp; Cromwell<BR>
125 Broad Street<BR>
New York, New York 10004-2498<BR>
(212) 558-4000</FONT></B>
</P>

<BR>
<HR SIZE=2 NOSHADE>
<PAGE>
<BR>

<HR SIZE=1 NOSHADE>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
     <TH COLSPAN=2>CALCULATION OF FILING FEE</TH>
</TR>
<TR>
     <TD WIDTH=50%>&nbsp;</TD>
     <TD WIDTH=50%>&nbsp;</TD>
</TR>
<TR>
     <TD ALIGN=CENTER>Transaction valuation <SUP>(1)</SUP></TD>
     <TD ALIGN=CENTER>Amount of filing fee<SUP>(2)</SUP></TD>
</TR>
<TR>
     <TD ALIGN=CENTER>$489,852,842</TD>
     <TD ALIGN=CENTER>$97,971</TD>
</TR>
</TABLE>

<HR SIZE=1 NOSHADE>

<P>
(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the offer to
purchase all of the outstanding shares of common stock of ADAC Laboratories
together with the associated rights to purchase Series A Junior Participating
Preferred Stock at a purchase price of $18.50 cash per share, 21,136,116 shares
outstanding and outstanding options with respect to 5,342,416 shares, in each
case as of November 12, 2000.
</P>
<P>
(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1% of 1/50<SUP>th</SUP>
of the transaction valuation.
</P>

<P>
[X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the box if any
part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing
with which the offsetting fee was previously paid. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its
filing.<BR>
Amount Previously Paid: $97,971<BR>
Form or Registration No.: 005-32403<BR>
Filing Party: Koninklijke Philips Electronics N.V.<BR>
Date Filed:November 14, 2000
</P>

<P>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the box if the
filing relates solely to preliminary communications made before the commencement
of a tender offer.

<P>
Check the appropriate boxes below to designate any transactions to which the
statement relates:<BR>
[X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;third-party tender
offer subject to Rule 14d-1.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issuer tender offer
subject to Rule 13e-4.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;going-private
transaction subject to Rule 13e-3.<BR>
[_]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;amendment to Schedule
13D under Rule 13d-2.

<P>
Check the following box if the filing is a final amendment reporting the results
of the tender offer:&nbsp;&nbsp;&nbsp;[X]
</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         This Amendment No. 9 ("Amendment No. 9") to Schedule TO amends and
supplements the Schedule TO filed with the Securities and Exchange Commission
("SEC") on November 14, 2000 (the "Original Schedule TO"), as amended by
Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, Amendment
No. 5, Amendment No. 6, Amendment No. 7 and Amendment No. 8 to the Original
Schedule TO (collectively, the "Schedule TO"), by Koninklijke Philips
Electronics N.V., Philips Holding USA Inc. and Philips Medical Acquisition
Corporation ("Merger Sub") relating to the tender offer (the "Offer") commenced
by Merger Sub, on November 14, 2000 to purchase all of the outstanding shares of
common stock, no par value, of ADAC Laboratories ("ADAC") together with the
associated rights to purchase Series A Junior Participating Preferred Stock of
ADAC, no par value, at a price of $18.50 per share, net to the sellers in cash,
upon the terms and subject to the conditions set forth in the Offer to Purchase,
dated November 14, 2000, and the related Letter of Transmittal.
</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         The information in the Schedule TO is hereby expressly incorporated
herein by reference in response to all the items of this Amendment No. 9, except
as otherwise set forth below. Capitalized terms used but not defined herein
shall have the meaning ascribed to them in the Original Schedule TO.
</P>

<P>&nbsp;</P>
<P ALIGN=CENTER>1</P>

<BR>
<HR SIZE=2 NOSHADE>
<PAGE>
<BR>

<H4 ALIGN=LEFT>
Item 4.&nbsp;&nbsp;&nbsp;Terms of the Transaction.
</H4>

<P>
Item 4 of the Schedule TO is hereby amended and supplemented to include the
following paragraph:
</P>
<P>
The tender offer expired at 1:00 p.m., New York City time, today, Monday,
December 18, 2000. At the expiration of the offer approximately 19,679,060 ADAC
Laboratories Shares had been validly tendered and not withdrawn pursuant to the
tender offer, not including approximately 197,533 Shares covered by notices of
guaranteed delivery. All such Shares have been accepted for payment in
accordance with the terms of the offer. The number of Shares tendered represents
in excess of 90.56% of the issued and outstanding ADAC Shares. Pursuant to the
terms of the merger agreement, Philips will shortly complete its acquisition of
ADAC Laboratories by effecting a "short form" merger under California law, in
which the remaining ADAC Shares will be converted into the right to receive
$18.50 net per share in cash.
</P>

<H4 ALIGN=LEFT>
Item 11.    Additional Information.
</H4>
<P>
Item 11 of the Schedule TO is hereby amended and supplemented to include the
following sentence:
</P>
<P>
On December 18, 2000, Royal Philips issued a press release announcing the
expiration of the tender offer and the acceptance for payment of validly
tendered shares, which is attached as an exhibit hereto and incorporated herein
by reference.
</P>

<H4 ALIGN=LEFT>
Item 12.    Exhibits.
</H4>

<P>
Item 12 of the Schedule TO is hereby amended and supplemented to include the
following exhibit:
</P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=15%>99(a)(18)</TD>
<TD WIDTH=85%>    Text of press release issued by Royal Philips on December 18,
                  2000.<BR><BR></TD>
</TR>
</TABLE>

<P>&nbsp;</P>
<P ALIGN=CENTER>2</P>

<BR>
<HR NOSHADE SIZE=2>

<PAGE>
<BR>

<H4 ALIGN=CENTER>
                                    SIGNATURE
</H4>

<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         After due inquiry and to the best of our knowledge and belief, we
certify that the information set forth in this statement is true, complete and
correct.
</P>
<P>
Date: December 18, 2000
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR>
     <TD WIDTH=45%> </TD>
     <TD WIDTH=55%> </TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>PHILIPS MEDICAL ACQUISITION CORPORATION</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Belinda W. Chew</U><BR>
                                 Name:&nbsp;&nbsp;Belinda W. Chew<BR>
                                 Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President <BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>PHILIPS HOLDING USA INC.</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Belinda W. Chew</U><BR>
                                 Name:&nbsp;&nbsp;Belinda W. Chew<BR>
                                 Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Senior Vice President <BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        <B>KONINKLIJKE PHILIPS ELECTRONICS N.V.</B><BR>
<BR><BR>
                                 By: &nbsp;&nbsp;<U>/s/ Cor Boonstra</U><BR>
                                 Name:  &nbsp;&nbsp;Cor Boonstra<BR>
                                 Title: &nbsp;&nbsp;&nbsp;&nbsp;
                                        President, Chairman of the Board of Management<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        and the Group Management Committee<BR><BR><BR></TD>
</TR>
<TR>
     <TD>&nbsp;&nbsp;</TD>
     <TD>                        By: <U>/s/ Jan H.M. Hommen</U><BR>
                                 Name:  &nbsp;&nbsp;Jan H.M. Hommen<BR>
                                 Title: &nbsp;&nbsp;&nbsp;&nbsp;
                                        Executive Vice-President, Chief Financial<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        Officer, Member of the Board of Management<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                        and the Group Management Committee<BR><BR></TD>
</TR>
</TABLE>

<BR>
<HR NOSHADE SIZE=2>
<PAGE>
<BR>

<P ALIGN=CENTER>
                                  EXHIBIT INDEX
</P>

<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0 BORDER=0>
<TR VALIGN=BOTTOM>
<TD WIDTH=15%>EXHIBIT<BR>
              <U>NUMBER</U></TD>
<TD WIDTH=85%><U>EXHIBIT DESCRIPTION</U></TD>
</TR>

<TR VALIGN=BOTTOM>
<TD WIDTH=15%>&nbsp;</TD>
<TD WIDTH=85%>&nbsp;</TD>
</TR>


<TR VALIGN=TOP>
<TD WIDTH=15%>99(a)(18)</TD>
<TD WIDTH=85%>     Text of press release issued by Royal Philips on December 18,
                   2000.<BR><BR></TD>
</TR>
</TABLE>

<BR>
<HR SIZE=2 NOSHADE>
<BR>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(A).(18)
<SEQUENCE>2
<FILENAME>0002.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>


<HTML>
<HEAD>
<TITLE>
Press Release
</TITLE>
</HEAD>

<BODY>


<P ALIGN=RIGHT>
                                                               EXHIBIT 99(a)(18)
</P>

<P>
<B>PHILIPS COMPLETES TENDER OFFER FOR ADAC LABORATORIES; OVER 90.56% OF SHARES
TENDERED</B>
</P>

<P>
<B>Amsterdam, the Netherlands, and Milpitas, California - December 18, 2000</B>: Royal
Philips Electronics (AEX: PHI, NYSE: PHG) and ADAC Laboratories (NASDAQ: ADAC)
announced today the expiration of Philips' $18.50 per share cash tender offer
for all the issued and outstanding shares of common stock of ADAC Laboratories.
The offer expired at 1:00 p.m., New York City time, today, Monday, December 18,
2000.
</P>

<P>At the expiration of the offer approximately 19,679,060 ADAC shares had been
validly tendered and not withdrawn pursuant to the tender offer, not including
approximately 197,533 shares covered by notices of guaranteed delivery. All such
shares have been accepted for payment in accordance with the terms of the offer.
</P>

<P>The number of shares tendered represents in excess of 90.56% of the issued
and outstanding ADAC shares. Pursuant to the terms of the merger agreement,
Philips will shortly complete its acquisition of ADAC Laboratories by effecting
a &#147;short form&#148; merger under California law, in which the remaining
ADAC Laboratories shares will be converted into the right to receive $18.50 net
per share in cash.
</P>

<P>Commenting on the closing of the tender offer, Hans Barella, President and
CEO of Philips Medical Systems said, &#147;We are very pleased to have
successfully completed this transaction on schedule, and will now move fast to
bring our US operations together.&#148; </P>


<P><I>
For further information:<BR>
Ben Geerts, Philips Corporate Communications, tel: +31 20 5977215<BR>
Linda Snyder, ADAC Laboratories, tel: +1 408 468 3750
</I>
</P>
<P>
<B><U>ADAC Laboratories</U> is a worldwide market leader in nuclear medicine imaging
equipment and radiation therapy planning systems. The company offers a broad
range of nuclear medicine systems that are used primarily in the diagnosis of
heart disease and cancer. In addition, ADAC Laboratories is an emerging leader
in positron emission tomography (PET) imaging. PET provides physicians with
solutions for accurate cancer disease management. The market for PET systems has
grown dramatically in the past year due to expanded Medicare reimbursement, and
the widespread acceptance of PET in the U.S.A. for cancer diagnosis, staging and
treatment follow-up.</B>
</P>
<P>
<B>Royal Philips Electronics of the Netherlands is one of the world's biggest
electronics companies and Europe's largest, with sales of EUR 31.5 billion in
1999. It is a global leader in color television sets, lighting, electric
shavers, color picture tubes for televisions and monitors, and one-chip TV
products. Its 239,370 employees in more than 60 countries are active in the
areas of lighting, consumer electronics, domestic appliances,</B></P>

<BR>
<HR NOSHADE SIZE=2>

<PAGE>
<BR>

<P>
<B>components, semiconductors and medical systems. Philips is quoted on the NYSE
(symbol: PHG), London, Frankfurt, Amsterdam and other stock exchanges. News from
Philips is located at <U>www.news.philips.com</U></B>
</P>
<P>
<B><U>Philips Medical Systems</U> is a leader in diagnostic imaging and related services
and offers a robust portfolio, including Catheterization Labs, MR, CT, X-ray,
and ultrasound systems, as well as information technology solutions that address
the radiology, general imaging, surgical and cardiovascular markets.</B>
</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
